FIELD: medicine.
SUBSTANCE: present invention relates to gene therapy for treating eye diseases, more specifically to use vectors for conditional expression of one or more therapeutic protein under the control of gene expression modulation system in the presence of activating ligand in the preparing of a drug, and can be used in medicine.
EFFECT: present invention allows to engineer a conditional expression vectors, which can be used for treating macular degeneration or glaucoma in an individual.
10 cl, 40 dwg, 8 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONSTRUCTED CELLS, EXPRESSING MULTIPLE IMMUNOMODULATORS, AND THEREOF APPLICATION | 2009 |
|
RU2573912C2 |
| MODIFIED DENDRITE CELLS AND THEIR USE IN TREATMENT OF MALIGNANT TUMOURS | 2008 |
|
RU2484132C2 |
| MODIFIED DENDRITIC CELLS AND THEIR APPLICATION FOR MALIGNANT TUMOURS TREATMENT | 2013 |
|
RU2644210C2 |
| MODIFIED DENDRITIC CELLS AND USE THEREOF IN TREATING MALIGNANT TUMOURS | 2017 |
|
RU2711606C2 |
| POLYVALENT VIRAL VECTORS AND SYSTEM FOR PRODUCING THEREOF | 2005 |
|
RU2416646C2 |
| T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS | 2013 |
|
RU2653761C2 |
| SELF-INACTIVATED HELPER ADENOVIRUSES FOR PREPARING HIGH-CAPACITY RECOMBINANT ADENOVIRUSES | 2009 |
|
RU2520809C2 |
| NUCLEIC ACID SYNTHETIC MOLECULE (VERSIONS), MAMMAL CELL EXPRESSION VECTOR, MAMMAL HOST CELL AND METHOD OF EXPRESSING ANTIGEN PROTEIN OF HUMAN EPIDERMAL GROWTH FACTOR-2 (HER2/neu) OR SHORTENED FORM THEREOF | 2004 |
|
RU2397249C2 |
| INDUCIBLE PROMOTER, VECTOR AND HOST CELL BASED THEREON | 2021 |
|
RU2820059C2 |
| INSERTION OF TARGET GENE FOR IMPROVED CELLULAR IMMUNOTHERAPY | 2017 |
|
RU2824204C2 |
